Moschogiannis 2011.

Clinical features and settings	Study period: 2009 to 2010. Patient population: 99 patients with suspected neuroblastoma with¹²³I‐MIBG scans. Consecutive series: n.r. Time spans between symptoms and index test, between symptoms and reference standard and between index test and reference standard: n.r. Treatment between index test and reference standard: n.r.
Participants	Included patients: 32 children with suspected neuroblastoma and a ¹²³I‐MIBG scan at diagnosis. Median age: n.r. for these 32 included patients; for all 99 patients:range of 1 month to 8 years. Sex distribution: n.r. for these 32 included patients; for all 99 patients: 52 boys (53%), 47 girls (47%). INSS stage: n.r.
Study design	Cohort study. N.r. whether the study was retrospective or prospective.
Target condition and reference standard(s)	Target condition: newly diagnosed neuroblastoma. Reference standard: n.r.
Index and comparator tests	Index test: ¹²³I‐MIBG scintigraphy. Radiofarmacon: ¹²³I‐MIBG. Dose: n.r. Collimator: n.r. Matrix: n.r. Acquisition protocol: planar and SPECT images; a subtraction technique was applied (a kidney's image using 99mTc‐DMSA subtracted from the ¹²³I‐MIBG scan, achieving a better localization of the adrenal medulla as well as a more exact determination of adrenal uptake). Acquisition time: 24 hours after injection. Acquisition duration: n.r. SPECT: n.r. Interfering medication: n.r. Thyroid prophylaxis: stable iodide. Positive test result: pathological uptake. Number and expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Not published in full‐text (as of December 2012), but presented at the EANM conference 2011. Results n.r. for ¹²³I‐MIBG scans at first diagnosis separately from the ¹²³I‐MIBG scans during follow‐up. Contact information of the authors: not available.